Naloxone treatment in opioid addiction: The risks and benefits

Expert Opinion on Drug Safety

Volumn 6, Issue 2, 2007, Pages 125-132

  van Dorp, Eveline L A ^a   Yassen, Ashraf ^a   Dahan, Albert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

opioid receptor; opioid receptor antagonist; Addiction; Naloxone; Opioids

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CATECHOLAMINE; CLONIDINE; DIAMORPHINE; FENTANYL; ILLICIT DRUG; LOFEXIDINE; METHADONE; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NALTREXONE; NARCOTIC ANALGESIC AGENT; OPIATE; SUBUXONE; SUFENTANIL; UNCLASSIFIED DRUG;

ASYSTOLE; BLOOD BRAIN BARRIER; CARDIOVASCULAR DISEASE; CATECHOLAMINE RELEASE; COMA; CONTINUOUS INFUSION; DELIRIUM; DETOXIFICATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONJUGATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERANCE; GENERAL ANESTHESIA; HEART ARREST; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ABUSE; LUNG EDEMA; METHADONE TREATMENT; MONOTHERAPY; NONHUMAN; OPIATE ADDICTION; PAIN; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PLASMA HALF LIFE; RESPIRATION DEPRESSION; RESPIRATORY FAILURE; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SINGLE DRUG DOSE; TACHYCARDIA; VOMITING; WITHDRAWAL SYNDROME;

HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RECEPTORS, OPIOID, MU; RISK FACTORS;

EID: 33847735481     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.2.125     Document Type: Review

References (54)

1. BROWNSTEIN MJ: A brief history of opiates, opioid peptides and opioid receptors. Proc. Natl Acad. Sci. USA (1993) 90:5391-5393.
2. VOLKOW ND, LI TK: Drug addiction: the neurobiology of behaviour gone awry. Nat Rev. Neurosci. (2004) 5:963-970.
3. THIRION X, LAPIERRE V, MICALLEF J et al.: Buprenorphine presciption by general practitioners in a French region. Drug Alcahol Depend. (2002) 65:197-204.
4. CONTET C, KIEFFER BL, BEFORT K: Mu opioid receptor: a gateway to drug addiction. Curr. Opin. Neurobiol. (2004) 14:370-378.
5. MATTHES HWD, MALDONADO R, SIMONIN F et al.: Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature (1996) 383:819-823.
6. KREEK MJ, LAFORGE KS, BUTELMAN E: Pharmacotherapy of addictions. Nat. Rev. Drug Discov. (2002) 1:710-726.
7. KOOB GF: The neurocircuitry of addiction: Implications for treatment. Clin. Neurosci. Res. (2005) 5:89-101.
8. KOOB GF, LEMOAL M: Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat. Neurosci. (2005) 8:1442-1444.
9. O'CONNOR PG, FIELLIN DA: Pharmacologic treatment of heroin-dependent patients. Ann. Intern. Med. (2000) 133:40-54.
10. GOWING L, ALl R, WHITE J: Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst. Rev. (2006) 1:CD002021.
11. DAHAN A, YASSEN A, BIJL H et al.: Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br. J. Anaesth. (2005) 94:825-834.
12. YASSEN A, OLOFSEN E, DAHAN A, DANHOF M: Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J. Pharmacol. Exp. Ther. (2005) 313:1136-1149.
13. GONZALEZ JP, BROGDEN RN: Naltrexone - a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs (1988) 35:192-213.
14. MARTIN WR: Naloxone. Ann. Intern. Med (1976) 85:765-768.
15. KAUFMAN RD, GABATHULER ML, BELVILLE JW: Potency, duration of action and pA2 in man of intravenous naloxone measured by reversal of morphine-depressed respiration. J. Pharmacol. Exp. Ther. (1981) 219:156-162.
16. NGAI SH, BERKOWITZ BA, YANG JC, HEMPSTEAD J, SPECTOR S: Pharmacokinetics of naloxone in rats and in man - basis for its potency and short duration of action. Anesthesiology (1976) 44:398-401.
17. HANDAL KA, SCHAUBEN JL, SALAMONE FR: Naloxone. Ann. Emerg. Med. (1983) 12:438-445.
18. FLACKE JW, FLACKE WE, WILLIAMS GD: Acute pulmonary edema following naloxone reversal of high-dose morphine anesthesia. Anesthesiology (1977) 47:376-378.
19. MICHAELIS LL, HICKEY PR, CLARK TL et al.: Ventricular irritability associated with the use of naloxone. Ann. Thoracic Surg. (1974) 18:608-614.
20. TANAKA GY: Hypertensive reaction m naloxone. JAMA (1974) 228:25-26.
21. OSTERWALDER JJ: Naloxone for intoxications with intravenous heroin and heroin mixtures - harmless or hazardous? J. Toxicol Clin. Toxicol. (1996) 34:409-416.
22. BOYD JJ, KYTTA JV, AITTOMAKI JV, ROSENBERG PH, SEPPALA TA, RANDELL TT: Cardiovascular changes after naloxone administration in propofol-sedated piglets during opioid overdose. Acta Anaesthesiol. Scand. (2006) 50:1271-1276.
23. KAGAWA S, STAFFORD MJ, WAGGENER TB, SEVERINGHAUS JW: No effect of naloxone on hypoxia-induced ventilatory depression in adults. J. Appl. Physiol. (1982) 52:1030-1034.
24. GAL TJ: Naloxone reversal of buprenorphine-induced respiratory depression. Clin. Pharmacol. Ther. (1989) 45:66-71.
25. VAN DORP E, YASSEN A, SARTON E et al.: Naloxone reversal reversal of buprenorphine-induced respiratory depression. Anesthesiology (2006) 105:51-57.
26. GONZALEZ G, OLIVETO A, KOSTEN TR: Treatment of heroin (diamorphine) addiction - current approaches and future prospects. Drugs (2002) 62:1331-1343.
27. JOHANSSON BA, BERGLUND M, LINDGREN A: Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction (2006) 101:491-503.
28. GOLD CG, CULLEN DJ, GONZALES S, HOUTMEYERS D, DWYER MJ: Rapid opioid detoxificarion during general anesthesia. Anesthesiology, (1999) 91:1639-1647.
29. WHITE JM, IRVINE RJ: Mechanisms of fatal opioid overdose. Addiction (1999) 94:961-972.
30. GOLDFRANK L, WEISMAN RS, ERRICK JK, LO MW: A dosing nomogram for continuous infusion intravenous naloxone. Ann. Emerg. Med. (1986) 15:566-570.
31. GADDIS GM, WATSON WA: Naloxone-associated patient violence - an overlooked toxicity. Ann. Pharmacother. (1992) 26:196-198.
32. STRANG J, POWIS B, BEST D et al.: Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction (1999) 94:199-204.
33. LENTON SR, HARGREAVES KM: Should we conduct a trial of ditributing naloxone to heroin users for peer administration to prevent fatal overdose? Med. J. Aust. (2000) 173:260-263.
34. DARKE S, HALL W: The distribution of naloxone m heroin users. Addiction (1997) 92:1195-1199.
35. BACA CT, GRANT KJ: Take-home naloxone to reduce heroin death. Addiction (2005) 100:1823-1831.
36. DETTMER K, SAUNDERS B, STRANG J: Take home naloxone and the prevention of fatal heroin overdose: two pilot schemes. Br. Med. J. (2001) 322:895-896.
37. GALEA S, WORTHINGTON N, MARKHAM PIPER T, NANDI VV, CURTIS M, ROSENTHAL DNM: Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in NYC. Addict. Behav. (2006) 31:907-912.
38. STRANG J, KELLEHER M, BEST D, MAYET S, MANNING V: Emergency naloxone for heroin overdose. Br. Med. J. (2006) 333:614-615.
39. SPORER KA: Strategies for preventing heroin overdose. Br. Med J. (2003) 326:442-444.
40. GOWING LR, ALI RL: The place of detoxification in treatment of opioid dependence. Curr. Opin. Psychiatry (2006) 19:266-270.
41. COLLINS ED, KLEBER HD, WHITTINGTON RA, HEITLER NE: Anesthesia-assisted versus buprenorphine or donidine-assisted heroin detoxification and naltrexone induction - a randomized trial. JAMA (2005) 294:901-913.
42. DE JONG CAJ, LAHEIJ RJF, KRABBE PFM: General anesthesia does not improve outcome in opioid antagonist detoxificarion treatment: a randomized controlled trial. Addiction (2005) 100:206-215.
43. GOWING L, ALI R, WHITE J: Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database Syst. Rev. (2006) 2:CD002022.
44. GOWING L, FARRELL M, ALI R, WHITE J: Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst. Rev. (2004) 4:CD002024.
45. O'BRIEN C, GREENSTEIN R, TERNES J, WOODY G: Clinical Pharmacology of narcotic antagonists. Ann. NY Acad. Sci. (1978) 311:232-240.
46. VAN BRUSSEL GHA: Beperkte plaats van naltrexon bij de behandeling van opiaatverslaving. Ned. Tijdschr. Geneeskd (2001) 145:1452-1456.
47. JOHNSON RE, MCKAGH J: Buprenorphine and Naloxone for heroin dependence. Curr. Psychiatry Rep. (2000) 2:519-526.
48. STOLLER KB, BIGELOW GE, WALSH SL, STRAIN EC: Effects of buprenorphine/ naloxone in opioid-dependent humans. Psychopharmacology (Berl) (2001) 154:230-242.
49. FUDALA P, BRIDGE TP, HERBERT S et al.: Office based treatment of opiate addiction with a sublingual tablet formulation of buprenorphine and naloxone. N. Engl. J. Med. (2003) 349:949-958.
50. FIELLIN DA, PANTALON MV, CHAWARSKI MC et al.: Counseling plus buprenorphine maintenance therapy for opioid dependence. N. Engl. J. Med. (2006) 355:365-374.
51. CORREIA CJ, WALSH SL, BIGELOW GE, STRAIN EC: Effects associated with double-blind omission of buprenorphine/naloxone over a 98 h period. Psychopharmacology (Berl) (2006) 189:297-306.
52. COMER SD, WALKER EA, COLLINS ED: Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin dependent volunteers. Psychopharmacology (Berl) (2005) 181:664-675.
53. MENDELSON J, JONES RT, WELM S et al.: Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine stabilized, opiate-dependent volunteers. Psychopharmacology (Berl) (1999) 141:37-46.
54. ROBINSON GM, DUKES PD, ROBINSON BJ, COOKE RR, MAHONEY GN: The misuse of buprenorphine and naloxone in Wellington, New Zealand. Drug Alcohol Depend. (1993) 33:81-86.